Literature DB >> 31070995

Responders and nonresponders to pharmacotherapy and allergen immunotherapy.

Marek Jakalski1, Andrzej Bozek1, G Walter Canonica2.   

Abstract

Allergen immunotherapy (AIT) is a very useful therapy for allergic rhinitis. However, some patients do not achieve the expected results. The aim of the study was to investigate the potential factors that could affect the result, either good or poor, from AIT.
Methods: A retrospective analysis of 1624 patients with allergic rhinitis who underwent AIT and 1519 matched patients who underwent only symptomatic therapy (without AIT) was performed. Symptoms, medications scores and quality of life related to allergic diseases before and after therapy were recorded. Cluster analysis on all of the patients was performed to find any associations between responsiveness to therapy and the analyzed parameters. Responsiveness to therapy was assessed by the Mailing criteria.
Results: A total of 1266 (77.8%) patients from the AIT group met the criterion of 30% or greater improvement, and 1061 (65.2%) of these patients met the threshold of 60% or greater improvement according to the Mailing criteria. Patients who had a frequently better response to AIT were highly represented in the two clusters. There were subjects with a short history of allergic rhinitis and concomitant allergy to grass pollen or house dust mites. Patients with a prolonged duration of allergic rhinitis before therapy and with polysensitization were more frequently worse responders to AIT.
Conclusion: Responsiveness to therapy, including that to AIT, is difficult to assess. However, there were associations suggesting that short-term allergic rhinitis and monovalent allergies to grass pollen or mites could correspond to a better response to AIT.

Entities:  

Keywords:  IgE; Immunotherapy; allergic rhinitis; allergy; asthma

Mesh:

Substances:

Year:  2019        PMID: 31070995      PMCID: PMC6930103          DOI: 10.1080/21645515.2019.1614397

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  15 in total

Review 1.  Immunotherapy as an effective tool in allergy treatment.

Authors:  H J Malling
Journal:  Allergy       Date:  1998-05       Impact factor: 13.146

2.  EAACI Position paper on the standardization of nasal allergen challenges.

Authors:  J Augé; J Vent; I Agache; L Airaksinen; P Campo Mozo; A Chaker; C Cingi; S Durham; W Fokkens; P Gevaert; A Giotakis; P Hellings; M Herknerova; V Hox; L Klimek; C La Melia; J Mullol; N B Muluk; A Muraro; K Naito; O Pfaar; H Riechelmann; C Rondon; M Rudenko; B Samolinski; I Tasca; P Tomazic; K Vogt; M Wagenmann; G Yeryomenko; L Zhang; R Mösges
Journal:  Allergy       Date:  2018-03-27       Impact factor: 13.146

Review 3.  International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics.

Authors:  Marek Jutel; Ioana Agache; Sergio Bonini; A Wesley Burks; Moises Calderon; Walter Canonica; Linda Cox; Pascal Demoly; Antony J Frew; Robyn O'Hehir; Jörg Kleine-Tebbe; Antonella Muraro; Gideon Lack; Désirée Larenas; Michael Levin; Bryan L Martin; Harald Nelson; Ruby Pawankar; Oliver Pfaar; Ronald van Ree; Hugh Sampson; James L Sublett; Kazunari Sugita; George Du Toit; Thomas Werfel; Roy Gerth van Wijk; Luo Zhang; Mübeccel Akdis; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2016-02       Impact factor: 10.793

Review 4.  Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce.

Authors:  G W Canonica; C E Baena-Cagnani; J Bousquet; P J Bousquet; R F Lockey; H-J Malling; G Passalacqua; P Potter; E Valovirta
Journal:  Allergy       Date:  2007-03       Impact factor: 13.146

5.  GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe.

Authors:  L M Heinzerling; G J Burbach; G Edenharter; C Bachert; C Bindslev-Jensen; S Bonini; J Bousquet; L Bousquet-Rouanet; P J Bousquet; M Bresciani; A Bruno; P Burney; G W Canonica; U Darsow; P Demoly; S Durham; W J Fokkens; S Giavi; M Gjomarkaj; C Gramiccioni; T Haahtela; M L Kowalski; P Magyar; G Muraközi; M Orosz; N G Papadopoulos; C Röhnelt; G Stingl; A Todo-Bom; E von Mutius; A Wiesner; S Wöhrl; T Zuberbier
Journal:  Allergy       Date:  2009-10       Impact factor: 13.146

6.  Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines.

Authors:  P J Bousquet; C Combescure; F Neukirch; J M Klossek; H Méchin; J-P Daures; J Bousquet
Journal:  Allergy       Date:  2007-04       Impact factor: 13.146

7.  Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy.

Authors:  Claire Gueguen; Julien Bouley; Hélène Moussu; Sonia Luce; Magalie Duchateau; Julia Chamot-Rooke; Marc Pallardy; Vincent Lombardi; Emmanuel Nony; Véronique Baron-Bodo; Laurent Mascarell; Philippe Moingeon
Journal:  J Allergy Clin Immunol       Date:  2015-10-29       Impact factor: 10.793

Review 8.  Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis.

Authors:  S Dhami; U Nurmatov; S Arasi; T Khan; M Asaria; H Zaman; Arnav Agarwal; G Netuveli; G Roberts; O Pfaar; A Muraro; I J Ansotegui; M Calderon; C Cingi; S Durham; R Gerth van Wijk; S Halken; E Hamelmann; P Hellings; L Jacobsen; E Knol; D Larenas-Linnemann; S Lin; P Maggina; R Mösges; H Oude Elberink; G Pajno; R Panwankar; E Pastorello; M Penagos; C Pitsios; G Rotiroti; F Timmermans; O Tsilochristou; E-M Varga; C Schmidt-Weber; J Wilkinson; A Williams; M Worm; L Zhang; A Sheikh
Journal:  Allergy       Date:  2017-07-14       Impact factor: 13.146

Review 9.  International consensus on allergy immunotherapy.

Authors:  Marek Jutel; Ioana Agache; Sergio Bonini; A Wesley Burks; Moises Calderon; Walter Canonica; Linda Cox; Pascal Demoly; Antony J Frew; Robin O'Hehir; Jörg Kleine-Tebbe; Antonella Muraro; Gideon Lack; Désirée Larenas; Michael Levin; Harald Nelson; Ruby Pawankar; Oliver Pfaar; Ronald van Ree; Hugh Sampson; Alexandra F Santos; George Du Toit; Thomas Werfel; Roy Gerth van Wijk; Luo Zhang; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2015-07-07       Impact factor: 10.793

Review 10.  Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews.

Authors:  Ulugbek Nurmatov; Sangeeta Dhami; Stefania Arasi; Graham Roberts; Oliver Pfaar; Antonella Muraro; Ignacio J Ansotegui; Moises Calderon; Cemal Cingi; Stephen Durham; Roy Gerth van Wijk; Susanne Halken; Eckard Hamelmann; Peter Hellings; Lars Jacobsen; Edward Knol; Desiree Larenas-Linnemann; Sandra Y Lin; Vivian Maggina; Hanneke Oude-Elberink; Giovanni Pajno; Ruby Panwankar; Elideanna Pastorello; Constantinos Pitsios; Giuseppina Rotiroti; Frans Timmermans; Olympia Tsilochristou; Eva-Maria Varga; Jamie Wilkinson; Andrew Williams; Margitta Worm; Luo Zhang; Aziz Sheikh
Journal:  Clin Transl Allergy       Date:  2017-08-08       Impact factor: 5.871

View more
  2 in total

Review 1.  Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ?

Authors:  Cristoforo Incorvaia; Erminia Ridolo; Marina Mauro; Francesco Pucciarini; Enrico Heffler; Giorgio Walter Canonica
Journal:  Front Allergy       Date:  2022-02-16

2.  Worsening of chronic house-dust-mite-induced respiratory allergies: An observational survey in three European countries.

Authors:  Pascal Demoly; Catherine Bos; Carmen Vidal
Journal:  World Allergy Organ J       Date:  2021-07-07       Impact factor: 4.084

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.